Xalkori Dosage
Generic name: crizotinib
Drug class: Multikinase inhibitors
Medically reviewed by A Ras MD.
Recommended Adult Dosing
Dosage forms: CAP: 200 mg, 250 mg
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
ALK- or ROS1-positive non-small cell lung CA, metastatic
- [250 mg PO bid]
- Info: do not open cap
ALK-positive inflammatory myofibroblastic tumor, unresectable, recurrent or refractory
- [250 mg PO bid]
- Info: do not open cap
ALK-positive systemic anaplastic large cell lymphoma, relapsed or refractory
- [BSA 0.6-0.8 m^2]
- Dose: 280 mg/m^2/dose PO bid (round to 200 mg PO bid); Info: for young adult pts; do not open cap
- [BSA 0.81-1.16 m^2]
- Dose: 280 mg/m^2/dose PO bid (round to 250 mg PO bid); Info: for young adult pts; do not open cap
- [BSA 1.17-1.51 m^2]
- Dose: 280 mg/m^2/dose PO bid (round to 400 mg PO bid); Info: for young adult pts; do not open cap
- [BSA 1.52-1.69 m^2]
- Dose: 280 mg/m^2/dose PO bid (round to 450 mg PO bid); Info: for young adult pts; do not open cap
- [BSA >1.69 m^2]
- Dose: 280 mg/m^2/dose PO bid (round to 500 mg PO bid); Info: for young adult pts; do not open cap
Renal dosing
- [non-small cell lung CA or inflammatory myofibroblastic tumor]
- CrCl <30: 250 mg qd
- HD/PD: not defined
- [anaplastic large cell lymphoma, BSA 0.6-0.8 m^2]
- CrCl <30: avoid use
- HD/PD: not defined
- [anaplastic large cell lymphoma, BSA 0.81-1.16 m^2]
- CrCl <30: 250 mg qd
- HD/PD: not defined
- [anaplastic large cell lymphoma, BSA 1.17-1.69 m^2]
- CrCl <30: 200 mg bid
- HD/PD: not defined
- [anaplastic large cell lymphoma, BSA >1.69 m^2]
- CrCl <30: 250 mg bid
- HD/PD: not defined
Hepatic dosing
- [non-small cell lung CA or inflammatory myofibroblastic tumor]
- bilirubin 1.6-3x ULN and any AST: 200 mg bid; bilirubin >3x ULN and any AST: 250 mg qd
- [anaplastic large cell lymphoma, BSA 0.6-0.8 m^2]
- bilirubin 1.6-3x ULN and any AST: 250 mg qd; bilirubin >3x ULN and any AST: avoid use
- [anaplastic large cell lymphoma, BSA 0.81-1.16 m^2]
- bilirubin 1.6-3x ULN and any AST: 200 mg bid; bilirubin >3x ULN and any AST: 250 mg qd
- [anaplastic large cell lymphoma, BSA 1.17-1.69 m^2]
- bilirubin 1.6-3x ULN and any AST: 250 mg bid; bilirubin >3x ULN and any AST: 200 mg bid
- [anaplastic large cell lymphoma, BSA >1.69 m^2]
- bilirubin 1.6-3x ULN and any AST: 400 mg bid; bilirubin >3x ULN and any AST: 250 mg bid
SRC: NLM .